Abstract
The relationships between structure, disintegration and antituberculotic in vitro activity were studied for over 200 derivatives of isonicotinic acid hydrazide (isoniazid, INH). Conclusive evidence reflects that many compounds do not withstand the in vitro conditions. A pH dependant partial hydrolysis to INH occurs in the case of hydrazones, in analogy to well-known benzoic acid esters. Hydrazides and amides are cleaved into isonicotinic acid. In general, antimycobacterial potencies drop against INH except for two outliers probably with additional unspecific toxicity of their residues. Analyzing the complexity and heterogeneity of molecular events, trends linked to hydrolysis are found when structural features are clustered. Hammett sigma constants correlate to pKα values possessing a twofold descriptive meaning: (i) the cardinal increase of partial positive charge of the reaction center towards nucleophilic water attack and (ii) the ionization crucial for mycobacterial cell permeation through porins or lipid barriers. We review the literature concluding that many so-called "novel leads" are nothing else than precursors of an INH-based scaffold. In addition, INH ringsubstitution or analogous backbones never achieve the efficiency of INH, itself a prodrug, which accumulates in Mycobacterium tuberculosis in form of its intrabacterial active principle(s) to which it is an optimal transport vehicle, evidencing that INH is not a promising lead compound at all.
Keywords: Hydrazones, Hydrazides, Hydrolysis, Isoniazid, Mycobacterium, Tuberculosis, QSAR
Current Medicinal Chemistry
Title: Isoniazid is Not a Lead Compound for its Pyridyl Ring Derivatives,Isonicotinoyl Amides, Hydrazides, and Hydrazones: A Critical Review
Volume: 13 Issue: 18
Author(s): T. Scior and S. J. Garces-Eisele
Affiliation:
Keywords: Hydrazones, Hydrazides, Hydrolysis, Isoniazid, Mycobacterium, Tuberculosis, QSAR
Abstract: The relationships between structure, disintegration and antituberculotic in vitro activity were studied for over 200 derivatives of isonicotinic acid hydrazide (isoniazid, INH). Conclusive evidence reflects that many compounds do not withstand the in vitro conditions. A pH dependant partial hydrolysis to INH occurs in the case of hydrazones, in analogy to well-known benzoic acid esters. Hydrazides and amides are cleaved into isonicotinic acid. In general, antimycobacterial potencies drop against INH except for two outliers probably with additional unspecific toxicity of their residues. Analyzing the complexity and heterogeneity of molecular events, trends linked to hydrolysis are found when structural features are clustered. Hammett sigma constants correlate to pKα values possessing a twofold descriptive meaning: (i) the cardinal increase of partial positive charge of the reaction center towards nucleophilic water attack and (ii) the ionization crucial for mycobacterial cell permeation through porins or lipid barriers. We review the literature concluding that many so-called "novel leads" are nothing else than precursors of an INH-based scaffold. In addition, INH ringsubstitution or analogous backbones never achieve the efficiency of INH, itself a prodrug, which accumulates in Mycobacterium tuberculosis in form of its intrabacterial active principle(s) to which it is an optimal transport vehicle, evidencing that INH is not a promising lead compound at all.
Export Options
About this article
Cite this article as:
Scior T. and Garces-Eisele J. S., Isoniazid is Not a Lead Compound for its Pyridyl Ring Derivatives,Isonicotinoyl Amides, Hydrazides, and Hydrazones: A Critical Review, Current Medicinal Chemistry 2006; 13 (18) . https://dx.doi.org/10.2174/092986706777935249
DOI https://dx.doi.org/10.2174/092986706777935249 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Iron Chelation and Drug Resistance in Cancer and Tuberculosis)
Current Pharmaceutical Biotechnology Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Anti-Inflammatory Effects of Antidepressants: Possibilities for Preventives Against Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry miRNAs Signatures In Patients With Acute Liver Injury: Clinical Concerns and Correlations
Current Molecular Medicine Discovering New Schistosome Drug Targets: The Role of Transcriptomics
Current Drug Targets Meet Our Editorial Board Member:
Current Medicinal Chemistry Patent Selections:
Recent Patents on Drug Delivery & Formulation FDG-PET Imaging in Sarcoidosis
Current Medical Imaging Recent Advances in Methodologies for the Discovery of Antimycobacterial Drugs
Current Bioactive Compounds Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Meet Our Editorial Board Member:
Current Medicinal Chemistry Nanoformulations of Moxifloxacin, Econozole and Ethionamide as Novel Treatment Regimens Against MDR TB - An Experimental Study
Current Nanoscience Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design New Insights in Design and Development of Antitubercular Drugs
Current Bioactive Compounds Evaluation of Various Diagnostic Techniques for the Diagnosis of Pulmonary and Extra Pulmonary Tuberculosis at a Tertiary Care Center in North India
Infectious Disorders - Drug Targets Ring Closing Metathesis in the Synthesis of Biologically Interesting Peptidomimetics, Sugars and Alkaloids
Current Topics in Medicinal Chemistry Archaeosome Immunostimulatory Vaccine Delivery System
Current Drug Delivery Newest Strategies in the Search for Bioactive Saponins from the Tropical Plant Biodiversity
Current Drug Delivery From Bench to Product: The Importance of Public-private Partnerships for the Immunological Diagnostic Kit Industry
Current Biotechnology